Journal Watch · Frontiers in Immunology · 2026

400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for booster vaccination.

Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

Yin Z, Yin M, Zhao F et al.Frontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1768679PMID: 41798948Study type: clinical study

TL;DR

Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

Key findings

  • The IgG threshold for protection against XBB reinfection was 400 AU/mL, and each additional vaccination reduced reinfection risk by 13-15%.<h4>Conclusion</h4>The 400 AU/mL IgG threshold provides a actionable quantitative guideline for prioritizing booster doses in Chinese adults aged ≥60 years (the fastest antibody decay subgroup) and high-risk groups.
  • Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

Numbers at a glance (from the abstract)

90%28%32.7%15%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively.<h4>Results</h4>A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds. Over three months, median IgG antibody levels declined by 28% (from 396.39 to 285.80 AU/mL). Prior infection and vaccination were significantly associated with higher antibody levels, while increasing age correlated with an annual decay of 0.38 AU/mL (most prominent in adults ≥60 years, 32.7% of whom fell below the protective threshold by follow-up).

Full abstract (original)

Background: <h4>Background</h4>Data on antibody dynamics and protective threshold generated by infection with Omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly among populations that have primarily (>90%) received inactivated coronavirus disease 2019 (COVID-19) vaccines, remain limited. Using data from two large-scale paired serosurveys, we analyzed real-world changes in SARS-CoV-2 antibody levels associated with specific hybrid immunity.<h4>Methods</h4>The history of COVID-19 vaccination and SARS-CoV-2 infection were recorded for each participant. Serum samples collected at three-month intervals were analyzed for antibody levels against nucleocapsid (N) and spike (S) proteins using chemiluminescent microparticle immunoassay (CMIA).

What they did: Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively.<h4>Results</h4>A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds. Over three months, median IgG antibody levels declined by 28% (from 396.39 to 285.80 AU/mL). Prior infection and vaccination were significantly associated with higher antibody levels, while increasing age correlated with an annual decay of 0.38 AU/mL (most prominent in adults ≥60 years, 32.7% of whom fell below the protective threshold by follow-up).

Results & conclusions: The IgG threshold for protection against XBB reinfection was 400 AU/mL, and each additional vaccination reduced reinfection risk by 13-15%.<h4>Conclusion</h4>The 400 AU/mL IgG threshold provides a actionable quantitative guideline for prioritizing booster doses in Chinese adults aged ≥60 years (the fastest antibody decay subgroup) and high-risk groups. Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1768679 · PubMed 41798948.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

What type of study is this?

It is a clinical study, published in Frontiers in Immunology in 2026. Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively.<h4>Results</h4>A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1768679. PubMed ID: 41798948. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yin Z, Yin M, Zhao F et al.. 400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for booster vaccination.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1768679.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/400-au-ml-igg-protective-threshold-against-sars-cov-2-xbb-reinfection-in-768679/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides